Daily Roundup

KYP.ASX NEU.ASX LGP.ASX CCO.ASX HCL.ASX

Kinatico Reports Strong Q2 SaaS Revenue Growth

Kinatico Limited, a leading provider of know your people solutions, has reported continued strong growth in its SaaS revenue for the second quarter of the 2026 financial year. The company's Q2FY26 SaaS revenue was $4.9 million, up 42% from the prior corresponding period, and now represents 58% of total revenue (up from 46% in the prior period). Kinatico's H1FY26 total revenue was $17.6 million, an increase of 13% compared to the prior corresponding period. The company's H1FY26 SaaS revenue was $9.7 million, up 49% from the prior corresponding period.

Kinatico's CEO, Michael Ivanchenko, commented that the strong SaaS revenue growth is evidence of the success of the company's strategy, and that the launch of the new Kinatico Compliance solution has also resonated with both SMEs and large enterprises. Ivanchenko also noted that the company remains cash accretive, reflecting the operational leverage emerging in the business.

DAYBUE Net Sales Projected to Reach Approx US$700m in 2028

Neuren Pharmaceuticals' partner Acadia Pharmaceuticals projects DAYBUE global net sales to reach approximately US$700 million in 2028, driven by the rollout of the DAYBUE STIX formulation, continued US growth, and international expansion. Since DAYBUE's launch in the US in 2023, more than 2,000 Rett syndrome patients have been treated by DAYBUE, and persistency at 12 months has now increased to 55%. Outside the US, Acadia announced the approval of DAYBUE oral solution by the Ministry of Health in Israel. The Phase 3 clinical trial of trofinetide in Japan is ongoing with top-line results expected between Q4 2026 and Q1 2027.

Transformational Merger of LGP and Cannatrek

Little Green Pharma (LGP) and Cannatrek have entered into a binding agreement for LGP to acquire 100% of Cannatrek, creating a leading vertically integrated medicinal cannabis group with operations in Australia and Europe. The combined entity is expected to have $112 million in revenue, $13 million in Adjusted EBITDA and $15 million in cash based on 2025 financial results. Synergies are expected from leveraging manufacturing capabilities, combining clinic and distribution assets, and optimizing costs. The transaction will also accelerate the expansion of LGP's European operations, which is expected to be a key growth driver.

Record Monthly Sales Result of $910k for The Calmer Co. International

The Calmer Co. International Limited (ASX: CCO) has achieved its highest ever monthly revenue of $910,767 in December 2025, driven by strong performance across all sales channels including Australian grocery, USA Amazon and B2B ingredient sales. The wholesale channel recorded its strongest monthly revenue of $340,131, with year-to-date wholesale sales already exceeding total FY25 annual wholesale revenue in the first half of FY26.

HighCom Ltd Reports H1 FY26 Trading Update

HighCom Limited (ASX: HCL) has provided a trading update for the first half of FY26. The company expects revenue and EBITDA loss for H1 to be in the range of $10.5 to $11.0 million, and $(5.0) to $(5.8) million respectively. This result is primarily due to the temporary shutdown of the US Government during H1, which slowed and delayed contract awards, procurement activity, and revenue recognition across the company's US operations. However, the company expects 2H FY26 revenue to exceed 1H FY26 and is targeting a material improvement in EBITDA in the second half.

HighCom Appoints New Executive Chairman and CEO

HighCom Limited has announced the appointment of Mr Geoffrey Knox as the new Executive Chairman of the Board and Chief Executive Officer, effective immediately. Mr Knox brings more than 40 years of global executive and board-level experience across various sectors, including defence, infrastructure, mining, energy, transport, and advanced manufacturing. He has a proven track record of scaling complex engineering and services businesses and delivering major programs for government and blue-chip clients.